HVHarshit Verma

Harshit Verma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Harshit Verma has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing probiotic attributes and molecular characterization of Weissella confusa from barbari goat faeces using 16S rRNA

    by Prashant Pandey, Ajit Kumar, Harshit Verma, Debashis Roy, Mrinal Srivastava, Malyaj R. Prajapati, Shriya Rawat, Atul Gupta, Nishant Sharma

    The present study examined the probiotic potential and molecular characterization of Weissella confusa isolated from goat faeces using 16S rRNA gene sequencing. A total of 15 lactic acid bacterial isolates were obtained from 42 fresh faecal samples collected from healthy barbari goats. Based on morphological, biochemical, and molecular analyses, two isolates goat faecal-7 (GF-7) and goat faecal-8 (GF-8) (Genbank accession numbers: MZ314055.1 Weissella confusa India and MZ314055.2 Weissella confusa India) were identified as W. confusa with 99.2% similarity to reference sequences in GenBank. The isolates demonstrated significant probiotic attributes including acid tolerance (survival at pH 2.5), bile salt resistance (0.3% oxgall), adhesion to intestinal epithelial cells (34.2%), and antimicrobial activity against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923. Antibiotic susceptibility testing revealed sensitivity to ampicillin, chloramphenicol, and tetracycline, indicating their safety for potential probiotic applications. The strains produced lactic acid at a concentration of 8.4 g/L and exhibited β-galactosidase activity. Phylogenetic analysis confirmed that the isolates belong to the Weissella genus. The results indicate that W. confusa MZ314055.1 and MZ314055.2 possess probiotic characteristics suitable for functional food development and animal health enhancement.

  • Occurrence of antimicrobial resistance (AMR) pattern of Escherichia coli isolated from faecal samples of chicken

    by Harshit Verma, Shriya Rawat, Shailja Katoch, Atul Gupta, Rajeev Singh

    A total of fifty (50) faecal swabs from the poultry farms were collected for investigation of E. coli. The prevalence of E. coli was found 70% identified on basis of cultural, morphological and biochemical tests. Antimicrobial resistance pattern revealed highest resistance for cefoxitin (100%), followed by enrofloxacin (77%), nalidixic acid (66%), doxycycline hydrochloride (49%) and least resistance against nitrofurantoin (6%). The highest susceptibility wasto nitrofurantoin (94%), followed by amikacin (86%), gentamycin (71%), doxycycline hydrochloride (51%), chloramphenicol (68.6%) and streptomycin (69%) where as some isolates showed nominal sensitivity against the nalidixic acid (34%) and enrofloxacin (23%). AMR pattern suggested nitrofurantoin as the most effective drug against E. coli.

  • MICROBIOLOGICAL AND ANTIBIOGRAM STUDY OF BACTERIAL PATHOGENS ASSOCIATED WITH BOVINE MASTITIS IN AND AROUND MEERUT

    by Harshit Verma, Amit Kumar, Prabhat Kumar, Surendra Upadhyay, Anamika Bhordia, Jitender Singh

    A rise in the incidence of disease in a herd results in multiplied use of antimicrobials, which in turn increases the presence of antibiotic residues in milk and increased bacterial resistance to antimicrobials. Continued use of antibiotics in the remedy and prevention of diseases of dairy cows always needs to be scrutinized. With this background, we carried out the present study to screen the major pathogens of bovine mastitis circulating in and around Meerut, Uttar Pradesh, India and their sensitivity to frequently used antibiotics. 30 milk samples suspected for mastitis based on clinical manifestations were collected and processed for bacterial isolation, identification and culture sensitivity test. Among the isolates, 14 (46.67%) were Gram-positive bacteria, 11 (36.67 %) Gram negative and 5 (16.67 %) were mixed infection. The isolated mastitis dweller bacteria were Staphylococcus spp. (46.67 %), E. coli (36.67 %), and mixed infection spp. (16.67 %). The studies of in vitro antibiogram revealed gentamicin to be the most effective drug (93.34 %), followed by enrofloxacin (66.67 %), cefotaxime+clavulanic acid (63.34 %), ampicillin+sulbactam (60.00 %), chloramphenicol (60.00 %), amoxicillin+sulbactam (53.34 %), colistin (46.67 %), ciprofloxacin (40.00 %), oxytetracycline (33.34 %), streptomycin (33.34 %), amoxicillin + clavulanic acid (13.34 %) and ampicillin/cloxacillin (10.00 %) against the bacterial isolates from mastitis milk. These findings suggest bacterial resistance against commonly used advanced drugs and combination of drugs. Thus, it can help to develop guidelines for practitioners in the choice of the most appropriate antibiotic. The outcomes of study contribute to risk assessment of anti-microbial resistance (AMR) and provide a standard baseline for setting up and assessing control measures and structuring strategies to constrain AMR.


  • Open Access

    Active Immunization with Pasteurella multocida Lysate Elicits Antibody that Protects Rabbits against Virulent Pasteurella multocida and Protects Mice by Passive Immunization

    by R. Durairajan, Harshit Verma, Awadhesh Prajapati, Mohammed Abbas, Mayank Rawat, Rishendra Verma

    Background: Pasteurellosis is an economically important disease of livestock worldwide and vaccination is effective mean to control the disease outbreaks. One of alternative method for vaccine preparation could be the use of lytic phages as bacterial inactivating agents and employing “phage lysate immunogen” as an immunizing agent. Therefore, the study was undertaken to explore the protective immune response of novel phage lysate vaccine against Pasteurella multocida. Methods: A phage lysate vaccine of Pasteurella multocida was prepared using isolated lytic phage and subjected to vaccine response study in rabbits. In this experiment, two mouse fixed-dose of lysate was used and the prophylactic efficacies of lysates were evaluated in rabbits by passive mouse protection test (PMPT), western blotting and direct virulent challenge. Result: Passive transfer of antibodies to mice using post-immunization sera of rabbits protected the animals against the challenge with A: 1 strain (75%) and B: 2 strain (50%). In western blotting, a total number of 4 bands were observed in the region between 130 kDa to 25 kDa in the protein of the phage lysate. The study suggested the significance increase in humoral immunity by phage lysate in murine Pasteurellosis.


  • Open Access

    Integration of tobacco cessation and tuberculosis management by NGOs in urban India: a mixed-methods study

    by H. A. Gupte, R. Zachariah, K. D. Sagili, V. Thawal, L. Chaudhuri, H. Verma, A. Dongre, A. Malekar, N. A. Rigotti

    Setting and objectives: Tobacco use compromises tuberculosis (TB) treatment outcomes. Tobacco cessation is beneficial to TB patients at the individual level and from the perspective of a larger spectrum of non-communicable diseases associated with tobacco use. We assessed feasibility, effectiveness and provider perceptions on integrating brief tobacco cessation advice into routine TB care by DOTS providers from 27 TB treatment centres run by three non-governmental organisations (NGOs) in urban India. Design: A mixed-methods study (triangulation design) involving analysis of programme data and semi-structured interviews (quantitative) and thematic analysis of focus group discussions of TB treatment providers (qualitative) regarding brief advice and cessation support provided to self-reported tobacco users from August 2015 to July 2017. Results: All 27 centres initiated tobacco cessation. Of 2132 registered TB patients, 377 (18%) were tobacco users, 333 (88%) of whom used smokeless tobacco. There was a progressive drop in documentation of tobacco status at each visit, reaching respectively 36% and 30% at the end of treatment for new and retreatment TB patients. Seven-day point prevalence abstinence at 6 months was 32% among new and 15% among retreatment cases. Enablers for integration included NGO collaboration, supervision and capacity building. Challenges included providers spending 15–45 min per patient (10 min recommended), multiple addictions, documentation load, self-reporting and social normalisation of tobacco. Conclusions: Integration of tobacco cessation into routine TB care in an urban NGO setting was feasible, although without continued support, rigour in documentation declined. This should be scaled up with special attention paid to tackling smokeless tobacco and related operational challenges.